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control in this population. Specifically, it is unknown whether the normal nocturnal decline 
in BP is present in patients with LVAD. 
METHODS: Twenty-four hour ambulatory BP and LVAD rate were measured in 10 
patients (six males/four females, mean age 54 ± 13 years) who had received a LVAD for 
cardiogenic shock. Etiology of cardiac dysfunction was ischemic in four patients, non- 
ischemic in five patients, and hypertrophic in one patient. Patients were clinically stable 
out of the intensive care unit and were not on inotropic support. Nine of the patients were 
on anti-hypertensive therapy. 
RESULTS; When comparing daytime and nighttime mean readings, there was no signifi- 
cant change in systolic, diastolic, or mean BP or in LVAD rate. 
CONCLUSION: Similar to patients with congestive heart failure or cardiac transplanta- 
tion, patients with LVAD lack a normal nocturnal decline in BP. This abnormal paffem of 
BP increases the cumulative work of the device by continuous 24 hour exposure to high 
afterload. Therefore, more aggressive treatment of hypertension in patients with left ven- 
tricular assist devices may be warranted to reduce the lanai-term workload of the device. 
Vital Sign Day (8AM-8PM) Night (12AM-6AM) p Value 
Systolic Blood Pressure (mm Hg) 125 + t0 120 ± 12 NS 
Diastolic Blood Pressure (mm Hg) 72 ± 11 69 ± 10 NS 
Mean Arterial Pressure (rnm Hg) 90 ± 8 87 ± 9 NS 
LVAD Rate (beats/min) 75 + 19 75 + 20 NS 
by fortnightly intramuscular injection. Exercise tolerance was assessed by the incremen- 
tal shuttle walk test; symptoms by NYHA class, Minnesota Living with Heart Failure 
(MLHF) score and Beck Depression Inventory (BDI); cardiac function by echocardio- 
graphy. Skeletal muscle bulk was estimated by CT-computed cross-sectional area of 
mid-thigh and mid-calf muscle; hand-grip strength was measured by dynamometry. Data 
are as mean±SD and were analysed by Wilcoxon matched pairs and Mann-Whitney U 
test. 
Result=l: Baseline characteristics did not differ significantly between groups. Mean test- 
osterone level at baseline was 12.71-6.4nM (normal range 10-37nM). Exercise distance 
increased markedly in the active treatment group (from 328+174m to 419±200m, p=0.01) 
but not in the placebo group (from 314±92m to 340~101m, p=0.12). The increase in walk 
distance in the two groups differed significantly (28% v 8% increase, p=0.015). NYHA 
class improved with treatment (from 2.3_+0.5 to 1.9±0.7. p=0.046), as did MLHF score 
(34.5±29.2 to 26.5:~:25.2, p=0.05) and BDI score (7.3±7.3 to 5.7~6.0, p=0.03). There 
were no changes in left ventricular function or in measures of skeletal muscle bulk and 
grip strength. 
Conclusion: In a pilot study, testosterone therapy for men with chronic heart failure 
improved exercise duration, symptom scores and mood with no apparent effect on LV 
function or skeletal muscle and no reported adverse effects. This may prove a useful 
add-on therapy for improving functional capacity and symptoms in these patients. 
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808-5 Ident i f i cat ion of  Left  Ventricular Recovery on 
Mechanical Assist Devices: Acute Suppor t  for  
Postcardiotomy Shock Versus Chronic Support as a 
Bridge to Transplant 
John Gorcsan. III. Donald A. Severyn, Badley P. Gdffith, Robert L. Karmas, University of 
Pittsburg, Pittsburg, Pennsylvania. 
Left ventricular assist devices (LVAD) can be life saving for acute heart failure (HF) asso- 
ciated with post-cardiotomy shock and also severe HF as a bridge to transplant. To test 
the hypothesis that quantitative echo measures can detect LV recovery on LVAD support, 
23 pts were studied: 11 with LVAD for acute post-cardiotomy shock (support duration 5±1 
d) and 12 with LVAD as bridge to transplant (support 276±191 d). Acute devices were 6 
Abiomed, 5 Biomedicus. Chronic devices were 6 Novacor, 6 Thoratec. LV end-diastolic 
and end-systolic area measures were made during full VAD support (acute flow=4.5±0.5, 
chronic flow=6.1+l.3L/min) and during decreases in VAD flow (acute 
flow=l.6+0.6,chronic flow=3.0±O.6L/min). 8 patients with acute support and 4 with 
chronic support had successful LVAD removal and survived to hospital discharge. Signif- 
icant differences were observed between the LV recovery patients on acute vs. chronic 
support as follows: % 8 in LV fractional area change (acute=77+55% vs chronic=- 
3+10%,p<0.05) and %8 in stroke area (acute=105±54% vs chronic=l 9±18%,p<0.05) fol- 
lowing weaning to low flow. Conclusions Quantitative echo detected LV recovery and 
predicted successful device removal in patients on both acute and chronic LVAD support. 
Recovery from acute shock was associated with greater degrees of LV functional 
improvement han patients on chronic support. Separate criteria need to be used to gov- 
ern the removal of devices with respect to duration of mechanical circulatory support. 
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810-2 Effect of Carvedllol on Major Clinical Events in Patients 
With Severe Heart Failure and an Extremely Depressed 
Ejection Fraction: Results of the COPERNICUS Study 
Hugo A. Katus, Michal Tendera, Paul Mohacsi, Jean L. Rouleau, Michael B. Fowler, 
Andrew J. Coats, Henry Krum, Terry L. Holcslaw, Ellen B. Roecker, Milton Packer, for the 
COPERNICUS Study Group., Universitaets-Klinikum Luebeck, Luebeck, Germany. 
Background: Despite the demonstrated survival benefit of ~-blockers in heart failure 
(HF), many physicians avoid the use of these drugs in patients with extremely depressed 
LV function in the belief that they will not respond favorably or may be adversely affected 
by treatment. 
Methods: Of the 2289 patients with severe HF enrolled in the COPERNICUS trial, 371 
patients had a baseline LV ejection fraction <= 15%. These patients had a lower mean 
systolic blood pressure (117 vs 125 mm Hg) and were more likely to be treated with digi- 
talis (73% vs 65%) than patients with higher EF (both P<0.002) but were otherwise simi- 
lar in their baseline characteristics. Both subgroups of patients were randomized to 
placebo (PBO) or carvedilol (CRY) for up to 29 months. 
Results: Shown below are 1-year Kaplan-Meier rates and risk reductions with CRV (Cox 
model). 
Ejection fraction <= 15% Ejection fraction • 15% 
PBO CRV Reduction PBO CRV Reduction in 
(n=191) (n=180) in risk (n=942) (n=976) risk 
All-cause 23.8% 18.9% 30% 17.4% 9.7% 36% 
mortality 
Death or hospitalization 46.3% 30.3% 39% 36.0% 24.6% 28% 
for worsening HF 
Death or cardiovascular 52.1% 34.6% 41% 39.4% 29.4% 23% 
hospitalization 
Death or any 59.9% 47.2% 33% 50.7% 40.4% 21% 
hospitalization 
The effects of CRV on all-cause mortality and on the risks of death or hospitalization (for 
any reason or for a specific cause) in patients with EF <= 15% were similar to those seen 
in patients with higher EF. CRV reduced the risk of permanent discontinuation of study 
drug in patients with EF <= 15% (by 32%) and in those with higher EF (by 19%). 
Conclusion: CRV is effective and well tolerated even in patients with severe HF symp- 
toms and an extreme depression of LV systolic function. 
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810-1 Testosterone Therapy Improves Exercise Duration and 
Symptoms in Men With Chronic Congestive Heart 
Failure 
Peter J. Push. John N. West, T. Hugh Jones, Kevin S. Channer, Department of 
Cardiology, Royal Ha/lamshire Hospital Sheffield, United Kingdom, Institute of 
Endocrinology, University of Sheffield Medical School Sheffield, United Kingdom. 
Background: Chronic heart failure (CHF) remains a major cause of morbidity, with terri- 
ble prognosis. Relative androgen deficiency reported in men with CHF could contribute 
to the pathophysiological processes of myocardial dysfunction, neuro-hormonal activa- 
tion, catabolic excess and muscle wasting and therefore to symptoms of exercise intoler- 
ance and dyspnoea. We examined the effects of androgen therapy on exercise duration, 
symptoms, cardiac function and skeletal muscle strength and bulk in men with CHF. 
Methods: In a double-blind trial, 20 men with CHF (age 61.5+8.5 years, ejection fraction 
34.8±7.8%) were randomised to 3 months treatment with testosterone 100mg or placebo 
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810-3 Nutritional Supplementation With MyoVive~D Repletes 
Essential Cardiac Myocyte Nutrients and Reduces Left 
Ventricular Size in Patients With Left Ventriculsr 
Dysfunction 
Farida Jeeieebhoy, Mary Keith, Michael Freeman, Aiala Barr, Michele McCall, Regina 
Kudan, David Mazer, Lea Errett, SL Michael's Hospital, Toronto, Ontado, Canada, 
University of Toronto, Toronto, Ontado, Canada. 
Background: Congestive heart failure (CHF) depletes the myocardium of camitine, coen- 
zyme Q10 (CoQ10) and taudne, substances known to influence mitochondrial function 
and cell calcium. We hypothesized that feeding patients a nutritional supplement which 
contains carnitine, CoQ10 and taurine would result in higher myocardial levels and 
improve left ventricular function. 
Methods: Forty-one aortocoronary artery bypass patients with an ejection fraction (EF)< 
40% at referral, were randomized to a double-blind trial of supplement (S) or placebo (P). 
Radionuclide ventriculography was performed at randomization (R) and just prior to sur- 
gery. Surgical myocardial biopsies, adjusted for protein content, were analyzed for car- 
nitine, CoQ10 and taurine levels. 
Results: The groups were well matched. Minor exceptions were S vs P for digoxin use (7 
versus 0 respectively p=0.0087) and age (62±11 versus 69±5 respectively, p=0.0395). 
There were significantly higher levels in the treated as compared to the placebo group for 
